Amneal Pharmaceuticals, Inc. Class A Common Stock Total Liabilities
Amneal Pharmaceuticals, Inc. Class A Common Stock total liabilities. Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has total liabilities worth $4.63 Billion USD as of September 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Amneal Pharmaceuticals, Inc. Class A Com liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
Total liabilities of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2025. This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore Amneal Pharmaceuticals, Inc. Class A Com long-term investment intensity to see how much of total assets are deployed in long-term investments.
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tongwei Co Ltd
SHG:600438
|
China | CN¥135.18 Billion |
|
Timken Company
NYSE:TKR
|
USA | $3.34 Billion |
|
WT Microelectronics Co Ltd
TW:3036
|
Taiwan | NT$688.06 Billion |
|
CarMax Inc
NYSE:KMX
|
USA | $19.76 Billion |
|
AURUBIS AG UNSP.ADR 1/2
F:NDA1
|
Germany | €4.49 Billion |
|
Eastman Chemical Company
NYSE:EMN
|
USA | $9.14 Billion |
|
InterDigital Inc
NASDAQ:IDCC
|
USA | $909.26 Million |
|
Hongfa Technology Co Ltd
SHG:600885
|
China | CN¥7.02 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Amneal Pharmaceuticals, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AMRX current and non-current assets.
Liquidity & Leverage Metrics
Amneal Pharmaceuticals, Inc. Class A Common Stock Total Liabilities Ratios Explained
Amneal Pharmaceuticals, Inc. Class A Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amneal Pharmaceuticals, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
The table below shows the annual total liabilities of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.67 Billion | +3.56% |
| 2024-12-31 | $3.55 Billion | +3.95% |
| 2023-12-31 | $3.41 Billion | -4.99% |
| 2022-12-31 | $3.59 Billion | +0.50% |
| 2021-12-31 | $3.57 Billion | -2.10% |
| 2020-12-31 | $3.65 Billion | +9.95% |
| 2019-12-31 | $3.32 Billion | -3.97% |
| 2018-12-31 | $3.46 Billion | +101.25% |
| 2017-12-31 | $1.72 Billion | +23.14% |
| 2016-12-31 | $1.39 Billion | +16.14% |
| 2015-12-31 | $1.20 Billion | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms … Read more